tbuckley/cabot-search huggingface dataset:
Hand-foot syndrome: Symptom assessment and the impact on quality of life—A review of the peer-reviewed literature
Authors: K. N. Keating, R. T. Anderson, J. J. O’Leary
Journal: Journal of Clinical Oncology (2008)

20685 Background: Hand-foot syndrome (HFS), also known as hand-foot skin reaction, palmar-plantar erythrodysesthesia, toxic erythema of the palms and soles, is an acute-onset symptom complex affecting the palms of the hands and soles of the feet, affecting up to 42% of patients treated with systemic chemotherapy agents. HFS has also been seen with newer oral agents, including Nexavar (sorafenib) and Sutent (sunitinib malate). With growth in use of oral antineoplastic agents, dose escalation studies and the use of combination regimens, it is important to understand the depth and breadth of patient reported symptoms and health-related quality of life impacts. If not recognized early and managed effectively, HFS can evolve from an initially mild cutaneous reaction to an extremely painful and debilitating condition with considerable impact on a patient’s quality of life. As an initial step in the development of an HFS symptom assessment and quality of life questionnaire (the HF-QoL), we conducted one of the first extensive reviews of the peer-reviewed medical literature to: 1) identify descriptors of concepts and experiences relevant to HFS, and 2) to describe the state of the science on HRQL with HFS. Methods: A search of the National Library of Medicine Gateway electronic database was conducted for articles in English, from 2000/01/01 to 2007/02/13. Two reviewers independently screened all titles and/or abstracts including quality of life and economic evaluations. The full manuscript of any study judged to be relevant by either and both reviewers was obtained and assessed for inclusion or exclusion based on criteria determined a priori. Results: In total, 267 titles and abstracts were screened for inclusion in the review. Full paper manuscripts of 61 citations were assessed and reviewed for inclusion. Results were compiled and summarized in table format to document the range of depth of data collected on HRQL with HFS. Conclusions: Of the scientific articles found that reported on HFS in the context of cancer treatment, none of these articles reported direct assessments of quality of life impact of HFS. Instead, the literature has been limited to describing and/or grading toxicity. HRQL assessments are needed to better document the impact of HFS. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Bayer Bayer Bayer, Bayer/Onyx
Mononuclear Cell Fraction Carrying Herpesvirus saimiri in Persistently Infected Squirrel Monkeys 2 3
Authors: John Wright, Lawrence A. Falk, Daniel Collins, Friedrich Deinhardt
Journal: JNCI Journal of the National Cancer Institute (1976)

Circulating lymphocytes from squirrel monkeys persistently infected with Herpesvirus saimiri (HVS) were separated into B- and T-lymphocyte fractions by a rosette-enrichment technique. HVS was isolated only from lymphocyte fractions forming rosettes or from unseparated lymphocytes; this indicated that T-lymphocytes were the target cells for HVS in the natural host, squirrel monkeys.
Interim Positron Emission Tomography Response–Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study
Authors: Pier Luigi Zinzani, Alessandro Broccoli, Daniela Maria Gioia, Antonio Castagnoli, Giovannino Ciccone, Andrea Evangelista, Armando Santoro, Umberto Ricardi, Maurizio Bonfichi, Ercole Brusamolino, Giuseppe Rossi, Antonella Anastasia, Francesco Zaja, Umberto Vitolo, Vincenzo Pavone, Alessandro Pulsoni, Luigi Rigacci, Gianluca Gaidano, Caterina Stelitano, Flavia Salvi, Chiara Rusconi, Monica Tani, Roberto Freilone, Patrizia Pregno, Eugenio Borsatti, Gian Mauro Sacchetti, Lisa Argnani, Alessandro Levis
Journal: Journal of Clinical Oncology (2016)

Purpose The clinical impact of positron emission tomography (PET) evaluation performed early during first-line therapy in patients with advanced-stage Hodgkin lymphoma, in terms of providing a rationale to shift patients who respond poorly onto a more intensive regimen (PET response-adapted therapy), remains to be confirmed. Patients and Methods The phase II part of the multicenter HD0801 study involved 519 patients with advanced-stage de novo Hodgkin lymphoma who received an initial treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and who underwent an early ifosfamide-containing salvage treatment followed by stem-cell transplantation if they showed a positive PET evaluation after two cycles of chemotherapy (PET2). The primary end point was 2-year progression-free survival calculated for both PET2-negative patients (who completed a full six cycles of ABVD treatment) and PET2-positive patients. Overall survival was a secondary end point. Results In all, 103 of the 512 evaluable patients were PET2 positive. Among them, 81 received the scheduled salvage regimen with transplantation, 15 remained on ABVD (physician’s decision, mostly because of minimally positive PET2), five received an alternative treatment, and two were excluded because of diagnostic error. On intention-to-treat analysis, the 2-year progression-free survival was 76% for PET2-positive patients (regardless of the salvage treatment they received) and 81% for PET2-negative patients. Conclusion Patients with advanced-stage Hodgkin lymphoma for whom treatment was at high risk of failing appear to benefit from early treatment intensification with autologous transplantation, as indicated by the possibility of successful salvage treatment in more than 70% of PET2-positive patients through obtaining the same 2-year progression-free survival as the PET2-negative subgroup.
A phase II feasibility study of concurrent docetaxel chemotherapy and radiation to chest wall and peripheral lymphatics after four cycles of AC chemotherapy in patients with high risk operable breast cancer. A trial of the Pakistan Cancer Research Group
Authors: A. Shaharyar, I. H. Shah, S. Abubaker, M. Hafeez, P. Shahina, A. Jameel, K. Shabbir, I. Randhawa, J. Akhtar
Journal: Journal of Clinical Oncology (2005)

858 Background: We have previously reported the feasibility of sequential use of docetaxel chemotherapy after four cycles of AC chemotherapy in early breast cancer (29th ESMO Congress, Abstract 252-P). Sequential use of docetaxel delays the use of postoperative radiation and can compromise the loco-regional control. We have designed this study to evaluate the feasibility of concurrent docetaxel and radiation therapy after four cycles of AC chemotherapy in patients with high risk operable breast cancer. Methods: Females between 18–50 years of age with T2-T3 lesions, four or more positive axillary lymph nodes and hormone receptor negative tumors were eligible. All patients had modified radical mastectomy. Four cycles of AC at 60/600mg/m2 were followed by four cycles of docetaxel at 75mg/m2. Concurrent radiation to chest wall and peripheral lymphatics was started with the third cycle of docetaxel. A dose of 50 Gy in 5 weeks or equivalent was delivered. Successful completion of treatment in 18 out of 20 patients was chosen as an index of feasibility. CTC version 2.0 of NCI was used. Results: All the twenty enrolled patients successfully completed the planned treatment. Radiation was completed within 6 months of surgery in 90%. Grade 1 radiation dermatitis was seen in 60% and grade 2 in 20%. Significant grade 3 toxicities included neutropenia and diarrhea in 25% and 20% respectively. Febrile neutropenia was seen in 15%. At a median follow up of 8 months (range 4–13 months) no local recurrence has been seen. Conclusions: This treatment schedule is feasible in patients with high-risk operable breast cancer. This is the first report incorporating concurrent use of docetaxel with chest wall irradiation. No significant financial relationships to disclose.
Is Dilute Russell’s Viper Venom Time a Useful Assay To Monitor Patients Treated By Rivaroxaban Or Dabigatran Etexilate?
Authors: Jonathan Douxfils, Anne Tamigniau, Bernard Chatelain, Bérangère Devalet, Pierre Wallemacq, Paul Hjemdahl, Yuko Rönquist-Nii, Jean-Michel Dogné, François Mullier
Journal: Blood (2013)
Mitochondrial DNA content in 30 paired blood and tissue samples of patients with breast cancer.
Authors: P. Xia, C. Li, C. X. Dang
Journal: Journal of Clinical Oncology (2010)

e21117 Background: Early detection of breast cancer has improved treatment and survival outcomes. However, tumor biomarkers validated and incorporated into oncology practice for the early diagnosis of breast cancer has not established. Alterations of mitochondrial DNA (mtDNA) have been implicated in carcinogenesis and tumor progression. We investigated the mtDNA content in paired Buffy-coat, plasma as well as in normal and cancerous tissue of patients with breast cancer to evaluate its diagnostic potential as biomarker. Methods: We developed an accurate multiplex quantitative real-time PCR for synchronized determination of mtDNA and nuclear DNA (nDNA). We investigated the levels of nDNA and mtDNA in 30 paired Buffy-coat and plasma blood samples from patients with breast tumors, and in 30 paired normal and cancerous breast tissue samples from the same patients. To evaluate the applicability of nDNA and mtDNA as a biomarker for distinguishing between the four study-groups we performed receiver operating characteristic (ROC) curve analysis. The content of mtDNA in buffy-coats groups was significantly lower than in other groups (overall p = 0.003). Reduced mtDNA was found in Buffy-coat samples (p = 0.002) and cancer tissue samples than normal tissues (p = 0.049). No difference in mtDNA content was observed in the plasma samples in comparison with normal tissues (p = 0.257). Using ROC curve analysis, we were able to distinguish between the buffy-coats groups and normal tissue samples using mtDNA content as marker (cut-off: 344; sensitivity: 80%; specificity: 67%; p = 0.011).Our results indicated decreased mtDNA content in Buffy-coat of patients with breast cancer may a promising approach for the development of biomarker regarding the sensitivity and specificity. Further large-scale validation studies are required to establish its potential use in early diagnosis and monitoring of breast cancer. No significant financial relationships to disclose.
Patterns and Efficacy of Bevacizumab Use Across Treatment Lines in Glioblastoma
Authors: M.B. Azam, Y.S. Rho, A. Mamo, S. Sahebjam, T. Muanza, M. Guiot, J. Al-Shami, R. Sharma, P. Kavan
Journal: Annals of Oncology (2014)
Ensuring the Quality of Quality Metrics for Emergency Care
Authors: James G. Adams
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase III, randomized, open-label study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): Findings from an interim safety analysis
Authors: M. Ducreux, A. Adenis, J. Bennouna, T. Conroy, R. Faroux, M. Hebbar, G. Lledo, B. Paillot, M. Ychou, J. Y. Douillard
Journal: Journal of Clinical Oncology (2005)

3596 Background: The oral fluoropyrimidine X has superior efficacy and improved safety compared with bolus 5-FU/LV in MCRC. Twice-daily oral X mimics 5-FU infusion and is replacing 5-FU in combination regimens. The combination of X and 3-weekly oxaliplatin (XELOX) has demonstrated good efficacy and safety in phase II clinical trials. We initiated a phase III trial to compare XELOX with FOLFOX-6 as first-line therapy in pts with MCRC. Here, we present the results of a planned interim safety analysis. Methods: From 16 May 2003 to 31 August 2004, 177 of a target of 304 pts have been randomized to receive either XELOX (91 pts: X 1000mg/m2 bid d1–14, oxaliplatin 130mg/m2 d1, q3w, maximum 8 cycles) or FOLFOX-6 (86 pts: 5-FU 400mg/m2 i.v. bolus then 2400–3000mg/m2 46-hour infusion, LV 400mg/m2 2-hour infusion, oxaliplatin 100mg/m2 d1, q2w, maximum 12 cycles). Demographics: male (61%)/female (39%); median age 64 (range 32–84) All patients had measurable MCRC, ECOG performance status 0–2, and normal hematologic, renal and hepatic function. Results: To date a median of 8 treatment cycles have been administered (XELOX median 6, range 1–8; FOLFOX median 9, range 1–12). Main adverse events (NCI-CTC) are listed in the table. Conclusions: These data show that XELOX and FOLFOX-6 are well tolerated in first-line MCRC. While XELOX causes more grade 1/2 hand-foot syndrome, it appears to cause less myelosuppression (particularly grade 3/4 neutropenia), stomatitis, neuropathy and paresthesia than FOLFOX-6. The planned enrollment of 304 pts will be complete in April 2005 and updated safety results will be reported at the meeting. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Roche Roche, sanofi-aventis
A randomized phase II trial of triplet or doublet antiemetic therapy in lung cancer patients receiving MEC (NLCTG1002)
Authors: Takao Miyabayashi, Satoru Miura, Hiroshi Tanaka, Takashi Ishida, Satoshi Watanabe, Masato Makino, Masaaki Okajima, Junta Tanaka, Hiroshi Kagamu, Hirohisa Yoshizawa
Journal: Annals of Oncology (2015)
DNA Content of Tumor Cells. III. Mosaic Composition of Sarcomas and Carcinomas in Man&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Stich, H. F., Steele, H. D.
Journal: JNCI Journal of the National Cancer Institute (1962)

Journal Article DNA Content of Tumor Cells. III. Mosaic Composition of Sarcomas and Carcinomas in Man Get access H. F. Stich, H. F. Stich Department of Biology and Department of Pathology, Queen's University, Kingston, Ontario, Canada Search for other works by this author on: Oxford Academic PubMed Google Scholar H. D. Steele H. D. Steele Department of Biology and Department of Pathology, Queen's University, Kingston, Ontario, Canada Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 28, Issue 5, May 1962, Pages 1207–1218, https://doi.org/10.1093/jnci/28.5.1207 Published: 01 May 1962 Article history Received: 03 January 1962 Published: 01 May 1962
Increasing the purity, potency and specificity of ebv-specific T cells to improve the treatment of EBV-positive lymphoma
Authors: Sandhya Sharma, Serena K Perna, Birju Mehta, Natalia Lapteva, Rayne Rouce, Carlos Ramos, Minhtran C Ngo, Vicky Torrano, Catherine M Bollard, Ann M Leen, Adrian P Gee, Helen Heslop, Cliona M Rooney
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Up to ~40 % of Hodgkin and non-Hodgkin lymphomas carry the Epstein-Barr virus (EBV) genome and express type 2 viral latency proteins (T2LPs) EBNA-1, LMP-1, LMP-2 and BARF-1. EBV specific T cells (EBVSTs) can be generated from the blood of EBV+ individuals, but are usually
Post-Recurrence Additional Chemotherapy is Feasible and Effective in Patients Undergoing Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
Authors: T. Takuwa, M. Hashimoto, A. Kuroda, S. Matsumoto, N. Kondo, T. Nakano, S. Hasegawa
Journal: Annals of Oncology (2014)
Metabolic Patterns in Cancer Cells and Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Tumor-Stromal Metabolic Coupling
Authors: Mahasweta Gooptu, Alina E Dulau Florea, Benjamin E Leiby, Barbara Pro, John David Sprandio, Diana whittaker-Menezes, Paolo Cotzia, Guldeep Uppal, Jaime Caro, Jerald Gong, Ubaldo Martinez-Outschoorn
Journal: Blood (2015)
Low frequency <i>KRAS</i> G12/13 mutations in urine cell-free (cf) DNA from patients with <i>BRAF</i> V600E-mutant advanced cancers.
Authors: Filip Janku, Cecile Rose T. Vibat, Gerald Steven Falchook, Helen J. Huang, David S. Hong, Sarina Anne Piha-Paul, Vivek Subbiah, Nishma M. Ramzanali, Saege Hancock, Aung Naing, Daniel D. Karp, Giovanni Nitti, Goran Cabrilo, Rajyalakshmi Luthra, Sapna Pradyuman Patel, Michael J. Overman, Scott Kopetz, Mark G. Erlander, Vlada Melnikova, Funda Meric-Bernstam
Journal: Journal of Clinical Oncology (2015)

11048 Background: Tumor heterogeneity and clonal selection contribute to resistance to molecular targeted therapies. Dynamic tracking of urine cfDNA mutations can offer a noninvasive tool for monitoring therapeutic efficacy. Methods: cfDNA was isolated from single or sequential urine samples from patients with advanced cancers and archival tumor tissue with BRAF V600E from a CLIA-certified laboratory. Assays for quantitative detection of BRAF V600E and KRAS G12/13 mutations in urine cfDNA were developed using digital droplet (dd) PCR and next generation sequencing. Analytical sensitivity of BRAF V600E and KRASG12/13 assays is 0.03% and 0.006% mutant alleles in wild-type DNA background. Results: Urine cfDNA was examined in 34 patients (melanoma, n = 11; colorectal cancer, n = 8; papillary thyroid carcinoma, n = 5; non-small cell lung cancer, n = 5; other, n = 5) with BRAF V600E in tumor tissue. 32 of 34 patients (94%) had the same mutation in urine cfDNA (mutant, n = 22; low-mutant, n = 10). Longitudinal analysis in 25 (74%) patients (treated with: BRAFi, n = 23; MEKi, n = 1; none, n = 1) showed that changes in BRAF V600E cfDNA amounts correlated with percent changes in target lesions on imaging (r = 0.68, p < 0.001). Patients with decreased BRAF V600E cfDNA (n = 16) compared to others (n = 8) had a trend to a longer median time-to-treatment failure (8.8 months, 95% CI 8.1-9.5 vs. 2.2 months, 95% CI 0.0-5.1; p = 0.07) on BRAF or MEK therapy. Moreover, 22 (65%) patients had a low frequency KRAS G12/13 mutation (median 3.4 copies/105 genome equivalents) in urine cfDNA that was previously undetected in tumor by CLIA, except in one case. 9 of 9 patients with urine examined at the time of progression had detectable cfDNA KRAS G12/13. Re-analysis of the retrieved archival tumor tissues from 8 patients found a previously undetected low frequency (1.3%) KRASmutation in one sample by ddPCR. Conclusions: Our results suggest that 65% of patients with advanced cancers and BRAF mutation in tumor tissue have low frequency KRAS G12/13 mutations in urine cfDNA undetected in tumor samples by standard CLIA technologies. Low frequency KRAS mutations can plausibly drive resistance to BRAF targeting agents, and these may be detected in urine cfDNA.
Radiographic location of the Dalkon Shield.
Authors: Mountrose Ue, White House Wl
Journal: BMJ (1974)

Uterine perforation is a potentially dangerous complication of the intrauterine contraceptive device.  The exact incidence of perforation is not known.  Hall reported an incidence of .5% perforation in 3988 insertions.  Suspicion of perforations is aroused when the threads cannot be seen at the cervix or have shortened appreciably and location of the device is then essential.  If this is not achieved by pelvic examination or by probing the uterus radiography is employed to exclude unnoticed expulsion.  Some intrauterine devices are easily seen on a plain x-ray.  The Dalkon Shield however has a lower level of radio opacity and unless certain x-ray techniques are used the device may be difficult or impossible to see.  The radio opacity is achieved by the addition of barium sulphate which has the undesirable effect to rendering the device more brittle.  To enable the Dalkon Shield to be bent during insertion through the cervical canal it must be as thin and as pliable as possible and the concentration of barium sulphate is therefore kept lower than in other devices.  3 techniques for the radiographic location of the Dalkon Shield are suggested for the average sized patient: 1) Regular technique: machine setting 200 mA 76 kV 3/5 sec. 2) Soft tissue technique A: machine setting 200 mA 76 kV 1/2 sec.  3) Soft tissue technique B: machine setting 200 mA 70 kV 2/5 -1/2 sec.  We would recommend the use of one of the above radiological techniques should radiographic location of a Dalkon Shield be required. (FULL TEXT)
The role of a copper transporter, ATP7A, in platinum resistance of esophageal squamous cell cancer (ESCC) and non-small cell lung cancer (NSCLC).
Authors: R. Xu, Z. Li, M. Oiu, F. Wang, H. Luo, W. Wu
Journal: Journal of Clinical Oncology (2010)

e13014 Background: The goal of this study was to determine the role of ATP7A in the platinum resistance of esophageal squamous cell carcinoma (ESCC) and non-small cell lung cancer (NSCLC). Methods: Platinum drugs' sensitivities were determined by MTT assay; multidrug resistance-related genes were analyzed by RT-PCR and immunoblotting. After Silencing ATPA in DDP-resistant cell sublines by siRNA, the changes in DDP sensitivies were determined by MTT assay and flow cytometry. The expression of ATP7A in clinical specimens of NSCLC patients who only received chemotherapy was evaluated by immunohistochemistry,and associations were sought between ATP7A expression and the clinicopathologic characteristics. Results: A549/DDP and EC109/DDP cell lines showed more resistant to DDP than A549 and EC109 cell lines, it also showed cross resistance to CBDCA and L-OHP. The expression of ATP7A was significantly higher in the A549/DDP and EC109/DDP than A549 and EC109 cell lines at both mRNA and protein levels. SiRNA duplexs targeting ATP7A was added into the A549/DDP and EC109/DDP cells, which successfully inhibited ATP7A expression, partially reversed DDP-resistance and increased cell death at different DDP concentrations. ATP7A was detected in 41.6% of 89 unresectable NSCLC patients who had only received platinum-based chemotherapy. The ATP7A-positive patients had a significantly lower histological grade (p=0.039) and worse response to platinum-based chemotherapy (p= 0.001) compared with the ATP7A-negative patients. Furthermore, the patients whose tumor tissue were ATP7A positive had a significantly poorer overall survival (p=0.021). Cox's proportional hazards model analysis showed ATP7A was a significantly independent factor for overall survival (p=0.045). Conclusions: ATP7A high expression plays an important role in platinum-resistance of ESCC and NSCLC, and could be a prognostic factor for NSCLC patients treated with platinum-based chemotherapy. Our study provided a new understanding of platinum resistance in ESCC and NSCLC and may have implications for therapeutic reversal of drug resistance. No significant financial relationships to disclose.
Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: An Update from the International Compassionate Use Program in 710 Patients
Authors: Selim Corbacioglu, Enric Carreras, Mohamad Mohty, Antonio Pagliuca, Maria Ballabio, Robin L. Hume, Valeria Bandiera, Giorgia Finetto, Paul G. Richardson
Journal: Blood (2014)